Abstract
The cancer originated from large bowel represents a widespread cancer along the world and a considerable percentage of new cases are diagnosed with distant disease. Recently, the detection of “clever” medicaments such as focused therapy was the outcome of an improved comprehension of the procedures that transform physiological tissues to tumor. The family of focused medication includes medicaments that specifically affect specific molecular routes implicated in the production of the tumor and its development. The new natural substances aim at inhibiting the procedure of angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February 26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as primary therapy in patients with large bowel tumor and distant metastases is analysed.
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Current Cancer Therapy Reviews
Title:Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy
Volume: 11 Issue: 2
Author(s): Georgios Koukourakis, Georgios Zacharias and Aristides Petridis
Affiliation:
Keywords: Avastin, bevacizumab, metastatic colorectal cancer.
Abstract: The cancer originated from large bowel represents a widespread cancer along the world and a considerable percentage of new cases are diagnosed with distant disease. Recently, the detection of “clever” medicaments such as focused therapy was the outcome of an improved comprehension of the procedures that transform physiological tissues to tumor. The family of focused medication includes medicaments that specifically affect specific molecular routes implicated in the production of the tumor and its development. The new natural substances aim at inhibiting the procedure of angiogenesis which is fundamental for cancer development and distant metastasis. This process of angiogenesis and tumor development is inhibited by Bevacizumab a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding. The usage of bevacizumab as primary therapy for patients with metastatic colorectal cancer was approved by FDA (Food and Drug Administration) on February 26, 2004. Incorporating the focused therapies in the management of metastatic colon cancer has led to considerable advance in efficiency results. In this review article, the effectiveness of bevacizumab given as primary therapy in patients with large bowel tumor and distant metastases is analysed.
Export Options
About this article
Cite this article as:
Koukourakis Georgios, Zacharias Georgios and Petridis Aristides, Primary Management of Metastatic Colorectal Cancer with Bevacizumab. Review Article Focusing on Efficacy, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711666151022203012
DOI https://dx.doi.org/10.2174/1573394711666151022203012 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics The Role of Reactive Oxygen Species in Tumor Treatment and its Impact on Bone Marrow Hematopoiesis
Current Drug Targets Traditional Uses, Therapeutic Effects and Recent Advances of Curcumin: A Mini-Review
Mini-Reviews in Medicinal Chemistry Changes in Glutathione, Oxidative Stress and Mitochondrial Membrane Potential in Apoptosis Involving the Anticancer Activity of Cantharidin Isolated from Redheaded Blister Beetles, Epicauta hirticornis
Anti-Cancer Agents in Medicinal Chemistry The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Identification of HDACs Inhibitor E14 Metabolites Appeared in Rat Plasma, Feces and Urine by UPLC-QTOF-MS/MS
Current Pharmaceutical Analysis Gene Expression Profiling and its Practice in Drug Development
Current Genomics High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
Current Cancer Drug Targets Needle in a Haystack: Targeting Specific Glucuronidases Amid the Human Microbiome
Current Enzyme Inhibition Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Strategies for Salt Reduction in Foods
Recent Patents on Food, Nutrition & Agriculture Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology